ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
11 announcements
Zota Health Care responded to a proxy advisory firm's negative recommendations on upcoming AGM resolutions, defending proposed director remuneration and related party transactions with its subsidiary.
Zota Health Care Limited announced the cessation of Mrs. Varshabahen Gaurang Mehta as an Independent Director effective September 09, 2026, upon the completion of her tenure.
Zota Health Care Limited appointed Mr. Mahaveer Dhariwal as a Non-Executive Independent Director, effective September 3, 2026. The board approved this leadership appointment.
Zota Health Care has fixed September 21, 2026, as the record date for its upcoming Annual General Meeting and final dividend payment.
Zota Health Care Limited's board approved the Notice of the 26th AGM and set the record date for the final dividend. They also appointed a new Independent Director.
Zota reported 67.6% YoY revenue growth in Q1 FY27, driven by Davaindia network expansion. Management expects EBITDA positivity to resume from Q2 and cash breakeven by Q1 FY28.
Zota Health Care's Q1FY27 presentation highlights its massive Davaindia retail generic pharmacy expansion, now reaching 2,825 stores and driving 83% of company revenue.
Zota Healthcare Ltd reported revenue from operations of ₹173.6 Cr (+67.6% YoY) and a net loss of ₹43.9 Cr for Q1 FY27.
Zota reported robust FY26 performance with 83.86% revenue growth, achieving EBITDA turnaround and significant Davaindia store expansion to 2,579 outlets.
Zota Health Care (FY26) achieved ₹53,865.75 lakhs revenue, driven by its Davaindia generic pharmacy retail chain which now spans 2,579 stores across 23 states.
Zota Healthcare Ltd reported revenue from operations of ₹163.2 Cr (+67.7% YoY) and a net loss of ₹14.5 Cr for Q4 FY26.